80_FR_23115 80 FR 23036 - National Vaccine Injury Compensation Program; List of Petitions Received

80 FR 23036 - National Vaccine Injury Compensation Program; List of Petitions Received

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Health Resources and Services Administration

Federal Register Volume 80, Issue 79 (April 24, 2015)

Page Range23036-23038
FR Document2015-09602

The Health Resources and Services Administration (HRSA) is publishing this notice of petitions received under the National Vaccine Injury Compensation Program (the Program), as required by Section 2112(b)(2) of the Public Health Service (PHS) Act, as amended. While the Secretary of Health and Human Services is named as the respondent in all proceedings brought by the filing of petitions for compensation under the Program, the United States Court of Federal Claims is charged by statute with responsibility for considering and acting upon the petitions.

Federal Register, Volume 80 Issue 79 (Friday, April 24, 2015) 
[Federal Register Volume 80, Number 79 (Friday, April 24, 2015)]
[Notices]
[Pages 23036-23038]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2015-09602]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration


National Vaccine Injury Compensation Program; List of Petitions 
Received

AGENCY: Health Resources and Services Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Health Resources and Services Administration (HRSA) is 
publishing this notice of petitions received under the National Vaccine 
Injury Compensation Program (the Program), as required by Section 
2112(b)(2) of the Public Health Service (PHS) Act, as amended. While 
the Secretary of Health and Human Services is named as the respondent 
in all proceedings brought by the filing of petitions for compensation 
under the Program, the United States Court of Federal Claims is charged 
by statute with responsibility for considering and acting upon the 
petitions.

FOR FURTHER INFORMATION CONTACT: For information about requirements for 
filing petitions, and the Program in general, contact the Clerk, United 
States Court of Federal Claims, 717 Madison Place NW., Washington, DC 
20005, (202) 357-6400. For information on HRSA's role in the Program, 
contact the Director, National Vaccine Injury Compensation Program, 
5600 Fishers Lane, Room 11C-26, Rockville, MD 20857; (301) 443-6593.

SUPPLEMENTARY INFORMATION: The Program provides a system of no-fault 
compensation for certain individuals who have been injured by specified 
childhood vaccines. Subtitle 2 of Title XXI of the PHS Act, 42 U.S.C. 
300aa-10 et seq., provides that those seeking compensation are to file 
a petition with the U.S. Court of Federal Claims and to serve a copy of 
the petition on the Secretary of Health and Human Services, who is 
named as the respondent in each proceeding. The Secretary has delegated 
this responsibility under the Program to HRSA. The Court is directed by 
statute to appoint special masters who take evidence, conduct hearings 
as appropriate, and make initial decisions as to eligibility for, and 
amount of, compensation.
    A petition may be filed with respect to injuries, disabilities, 
illnesses, conditions, and deaths resulting from vaccines described in 
the Vaccine Injury Table (the Table) set forth at Section 2114 of the 
PHS Act or as set forth at 42 CFR 100.3, as applicable. This Table 
lists for each covered childhood vaccine the conditions that may lead 
to compensation and, for each condition, the time period for occurrence 
of the first symptom or manifestation of onset or of significant 
aggravation after vaccine administration. Compensation may also be 
awarded for conditions not listed in the Table and for conditions that 
are manifested outside the time periods specified in the Table, but 
only

[[Page 23037]]

if the petitioner shows that the condition was caused by one of the 
listed vaccines.
    Section 2112(b)(2) of the PHS Act, 42 U.S.C. 300aa-12(b)(2), 
requires that ``[w]ithin 30 days after the Secretary receives service 
of any petition filed under section 2111 the Secretary shall publish 
notice of such petition in the Federal Register.'' Set forth below is a 
list of petitions received by HRSA on March 1, 2015, through March 31, 
2015. This list provides the name of petitioner, city and state of 
vaccination (if unknown then city and state of person or attorney 
filing claim), and case number. In cases where the Court has redacted 
the name of a petitioner and/or the case number, the list reflects such 
redaction.
    Section 2112(b)(2) also provides that the special master ``shall 
afford all interested persons an opportunity to submit relevant, 
written information'' relating to the following:
    1. The existence of evidence ``that there is not a preponderance of 
the evidence that the illness, disability, injury, condition, or death 
described in the petition is due to factors unrelated to the 
administration of the vaccine described in the petition,'' and
    2. Any allegation in a petition that the petitioner either:
    a. ``Sustained, or had significantly aggravated, any illness, 
disability, injury, or condition not set forth in the Vaccine Injury 
Table but which was caused by'' one of the vaccines referred to in the 
Table, or
    b. ``Sustained, or had significantly aggravated, any illness, 
disability, injury, or condition set forth in the Vaccine Injury Table 
the first symptom or manifestation of the onset or significant 
aggravation of which did not occur within the time period set forth in 
the Table but which was caused by a vaccine'' referred to in the Table.
    In accordance with Section 2112(b)(2), all interested persons may 
submit written information relevant to the issues described above in 
the case of the petitions listed below. Any person choosing to do so 
should file an original and three (3) copies of the information with 
the Clerk of the U.S. Court of Federal Claims at the address listed 
above (under the heading FOR FURTHER INFORMATION CONTACT), with a copy 
to HRSA addressed to Director, Division of Injury Compensation 
Programs, Healthcare Systems Bureau, 5600 Fishers Lane, Room 11C-26, 
Rockville, MD 20857. The Court's caption (Petitioner's Name v. 
Secretary of Health and Human Services) and the docket number assigned 
to the petition should be used as the caption for the written 
submission. Chapter 35 of title 44, United States Code, related to 
paperwork reduction, does not apply to information required for 
purposes of carrying out the Program.

    Dated: April 17, 2015.
James Macrae,
Acting Administrator.

List of Petitions Filed

1. Leanna Babb, Yuma, Arizona, Court of Federal Claims No: 15-0195V
2. Avery Kranz and Alyssa Kranz on behalf of M. K., Millburn, New 
Jersey, Court of Federal Claims No: 15-0196V
3. Avery Kranz, Millburn, New Jersey, Court of Federal Claims No: 
15-0197V
4. Carol Williams, Morgantown, West Virginia, Court of Federal 
Claims No: 15-0198V
5. Thomas Holland, Cataumet, Massachusetts, Court of Federal Claims 
No: 15-0199V
6. Mario Caruso, Clovis, California, Court of Federal Claims No: 15-
0200V
7. Marilyn Akyuz, Brooklyn, New York, Court of Federal Claims No: 
15-0201V
8. Andrew Bussa, Boston, Massachusetts, Court of Federal Claims No: 
15-0202V
9. Peggy Lafon, Crowley, Texas, Court of Federal Claims No: 15-0203V
10. Rosemary St. George, Boston, Massachusetts, Court of Federal 
Claims No: 15-0204V
11. David G. Smith, Billerica, Massachusetts, Court of Federal 
Claims No: 15-0205V
12. Carin Ing-Marie Malkin, Sarasota, Florida, Court of Federal 
Claims No: 15-0206V
13. Tamie Blesi, Minneapolis, Minnesota, Court of Federal Claims No: 
15-0208V
14. Tamie Blesi, Minneapolis, Minnesota, Court of Federal Claims No: 
15-0209V
15. James Collins, Jr., Concord, North Carolina, Court of Federal 
Claims No: 15-0210V
16. Annabella Chin, Pembroke, Florida, Court of Federal Claims No: 
15-0214V
17. Tisia Green, Cheektowaga, New York, Court of Federal Claims No: 
15-0218V
18. Tate Takahashi, Honolulu, Hawaii, Court of Federal Claims No: 
15-0219V
19. Dorothy Keegan, Rochester, New York, Court of Federal Claims No: 
15-0220V
20. Brandene LaPorte, Philadelphia, Pennsylvania, Court of Federal 
Claims No: 15-0221V
21. Melvin Keith Castle, New Bern, North Carolina, Court of Federal 
Claims No: 15-0222V
22. Sarah Yoon on behalf of N.Y., Valencia, California, Court of 
Federal Claims No: 15-0224V
23. Bernard Halverson on behalf of Susan Halverson, Deceased, Somers 
Point, New Jersey, Court of Federal Claims No: 15-0227V
24. Jean L. Buck, Las Vegas, Nevada, Court of Federal Claims No: 15-
0231V
25. Joseph Bourche, Boulder, Colorado, Court of Federal Claims No: 
15-0232V
26. Keith Saunders, Onawa, Iowa, Court of Federal Claims No: 15-
0233V
27. Mary Axelson on behalf of A. A., Phoenix, Arizona, Court of 
Federal Claims No: 15-0234V
28. Kristen Silverio on behalf of G. L., Phoenix, Arizona, Court of 
Federal Claims No: 15-0235V
29. Phyllis Phipps, Bluffton, Indiana, Court of Federal Claims No: 
15-0238V
30. Travis Morgan, Franklin, Tennessee, Court of Federal Claims No: 
15-0239V
31. Carl S. Fish, Folsom, California, Court of Federal Claims No: 
15-0244V
32. Rami Hatter, Dale City, California, Court of Federal Claims No: 
15-0245V
33. Tarah Gramza on behalf of J. G., Mesa, Arizona, Court of Federal 
Claims No: 15-0247V
34. Angela Bogue, Louisburg, North Carolina, Court of Federal Claims 
No: 15-0250V
35. Joseph Willett, Wake Forest, North Carolina, Court of Federal 
Claims No: 15-0252V
36. Scott Siciliano and Kathleen Siciliano on behalf of E. S., 
Smithtown, New York, Court of Federal Claims No: 15-0253V
37. Janet Florence, Glassboro, New Jersey, Court of Federal Claims 
No: 15-0255V
38. Allison Boman on behalf of R. B., Rock Springs, Wyoming, Court 
of Federal Claims No: 15-0256V
39. Jordan Holtz, Sussex, Wisconsin, Court of Federal Claims No: 15-
0257V
40. Robert Richie, Atoka, Oklahoma, Court of Federal Claims No: 15-
0258V
41. Sandra E. Horvath, San Jose, California, Court of Federal Claims 
No: 15-0260V
42. Lawrence Marra, Jr., Bethlehem, Pennsylvania, Court of Federal 
Claims No: 15-0261V
43. Ameena Jaafar on behalf of A. M., Windsor, Connecticut, Court of 
Federal Claims No: 15-0267V
44. Brian Badger, Owensboro, Kentucky, Court of Federal Claims No: 
15-0273V
45. John Harbrucker, Kansas City, Kansas, Court of Federal Claims 
No: 15-0274V
46. Maureen McGrath, Sturgeon Bay, Wisconsin, Court of Federal 
Claims No: 15-0275V
47. Jane Privitera, Baldwin, New York, Court of Federal Claims No: 
15-0276V
48. Raquel Davis on behalf of M. D., Boston, Massachusetts, Court of 
Federal Claims No: 15-0277V
49. Janice Schroeder, Austin, Texas, Court of Federal Claims No: 15-
0278V
50. Brittany Stallings Benoit and Arsene Benoit on behalf of Gabriel 
Cash Benoit, Deceased, Quitman, Mississippi, Court of Federal Claims 
No: 15-0279V
51. Annette Dominguez and Lydia Fazekas on behalf of Rebecca C. 
Arana, Deceased, Beverly Hills, California, Court of Federal Claims 
No: 15-0280V
52. Rita Glynn, St. Paul, Minnesota, Court of Federal Claims No: 15-
0283V
53. Malissa Ajeti, Gilroy, California, Court of Federal Claims No: 
15-0284V
54. Shawn Orgel-Olson, Boston, Massachusetts, Court of Federal 
Claims No: 15-0285V
55. George Swaiss, Santa Clara, California, Court of Federal Claims 
No: 15-0286V
56. Ann Wyborski, Vienna, Virginia, Court of Federal Claims No: 15-
0295V
57. Nadara Shives, Boston, Massachusetts, Court of Federal Claims 
No: 15-0296V
58. Joseph Sullivan, Sarasota, Florida, Court of Federal Claims No: 
15-0300V

[[Page 23038]]

59. Robert VanOsdol, Dallas, Texas, Court of Federal Claims No: 15-
0303V
60. Melissa Intini on behalf of Vanni Mae Intini, Fort Bragg, North 
Carolina, Court of Federal Claims No: 15-0304V
61. Erich Micheal Gram, Huntersville, North Carolina, Court of 
Federal Claims No: 15-0305V
62. Edward M. Haney, San Pablo, California, Court of Federal Claims 
No: 15-0310V
63. Charles Rohrer, Cedar Rapids, Iowa, Court of Federal Claims No: 
15-0311V
64. Jovan Ragia, Dallas, Texas, Court of Federal Claims No: 15-0312V
65. Karen Ryf, Oshkosh, Wisconsin, Court of Federal Claims No: 15-
0313V
66. Jaymeeni Patel, Atlanta, Georgia, Court of Federal Claims No: 
15-0318V
67. Angela Waters, Seneca, South Carolina, Court of Federal Claims 
No: 15-0320V
68. Beatrice Thomure, Boston, Massachusetts, Court of Federal Claims 
No: 15-0322V
69. Annmarie Auer, Boston, Massachusetts, Court of Federal Claims 
No: 15-0323V
70. Sara Olivia Cain, Raleigh, North Carolina, Court of Federal 
Claims No: 15-0325V
71. Nicholas Reinking and Hilary Katherine Reinking on behalf of M. 
R., Phoenix, Arizona, Court of Federal Claims No: 15-0326V
72. Philip Power and April Power on behalf of C. P., Cary, North 
Carolina, Court of Federal Claims No: 15-0327V
[FR Doc. 2015-09602 Filed 4-23-15; 8:45 am]
 BILLING CODE 4165-15-P

23036 Federal Register / Vol. 80, No. 79 / Friday, April 24, 2015 / Notices phase begins. The approval phase starts 3. The date the application was ACTION: Notice. with the initial submission of an approved: January 29, 2013. FDA has application to market the human drug verified the applicant’s claim that NDA SUMMARY: The Health Resources and product and continues until FDA grants 203568 was approved on January 29, Services Administration (HRSA) is permission to market the drug product. 2013. publishing this notice of petitions Although only a portion of a regulatory This determination of the regulatory received under the National Vaccine review period may count toward the review period establishes the maximum Injury Compensation Program (the actual amount of extension that the potential length of a patent extension. Program), as required by Section Director of USPTO may award (for However, the USPTO applies several 2112(b)(2) of the Public Health Service example, half the testing phase must be statutory limitations in its calculations (PHS) Act, as amended. While the subtracted as well as any time that may of the actual period for patent extension. Secretary of Health and Human Services In its application for patent extension, is named as the respondent in all have occurred before the patent was this applicant seeks 853 days of patent proceedings brought by the filing of issued), FDA’s determination of the term extension. petitions for compensation under the length of a regulatory review period for Anyone with knowledge that any of Program, the United States Court of a human drug product will include all the dates as published are incorrect may Federal Claims is charged by statute of the testing phase and approval phase submit to the Division of Dockets with responsibility for considering and as specified in 35 U.S.C. 156(g)(1)(B). Management (see ADDRESSES) either acting upon the petitions. FDA has approved for marketing the electronic or written comments and ask FOR FURTHER INFORMATION CONTACT: For human drug product KYNAMRO for a redetermination by June 23, 2015. information about requirements for (mipomersen sodium). KYNAMRO is Furthermore, any interested person may filing petitions, and the Program in indicated as an adjunct to lipid- petition FDA for a determination general, contact the Clerk, United States lowering medications and diet to reduce regarding whether the applicant for Court of Federal Claims, 717 Madison low density lipoprotein-cholesterol, extension acted with due diligence Place NW., Washington, DC 20005, apolipoprotein B, total cholesterol, and during the regulatory review period by (202) 357–6400. For information on non-high density lipoprotein-cholesterol October 21, 2015. To meet its burden, HRSA’s role in the Program, contact the in patients with homozygous familial the petition must contain sufficient facts Director, National Vaccine Injury hypercholesterolemia. Subsequent to to merit an FDA investigation. (See H. Compensation Program, 5600 Fishers this approval, the USPTO received a Rept. 857, part 1, 98th Cong., 2d sess., Lane, Room 11C–26, Rockville, MD patent term restoration application for 20857; (301) 443–6593. KYNAMRO (U.S. Patent No. 7,511,131) pp. 41–42, 1984.) Petitions should be in the format specified in 21 CFR 10.30. SUPPLEMENTARY INFORMATION: The from Genzyme Corporation, and the USPTO requested FDA’s assistance in Interested persons may submit to the Program provides a system of no-fault Division of Dockets Management (see compensation for certain individuals determining this patent’s eligibility for ADDRESSES) electronic or written who have been injured by specified patent term restoration. In a letter dated comments and written or electronic childhood vaccines. Subtitle 2 of Title March 27, 2014, FDA advised the petitions. It is only necessary to send XXI of the PHS Act, 42 U.S.C. 300aa– USPTO that this human drug product one set of comments. Identify comments 10 et seq., provides that those seeking had undergone a regulatory review with the docket number found in compensation are to file a petition with period and that the approval of brackets in the heading of this the U.S. Court of Federal Claims and to KYNAMRO represented the first document. If you submit a written serve a copy of the petition on the permitted commercial marketing or use petition, two copies are required. A Secretary of Health and Human of the product. Thereafter, the USPTO petition submitted electronically must Services, who is named as the requested that FDA determine the respondent in each proceeding. The product’s regulatory review period. be submitted to http:// www.regulations.gov, Docket No. FDA– Secretary has delegated this FDA has determined that the responsibility under the Program to applicable regulatory review period for 2013–S–0610. Comments and petitions that have not HRSA. The Court is directed by statute KYNAMRO is 2,601 days. Of this time, to appoint special masters who take 2,294 days occurred during the testing been made publicly available on http://www.regulations.gov may be evidence, conduct hearings as phase of the regulatory review period, appropriate, and make initial decisions while 307 days occurred during the viewed in the Division of Dockets Management between 9 a.m. and 4 p.m., as to eligibility for, and amount of, approval phase. These periods of time compensation. were derived from the following dates: Monday through Friday. A petition may be filed with respect 1. The date an exemption under Dated: April 20, 2015. to injuries, disabilities, illnesses, section 505(i) of the Federal Food, Drug, Leslie Kux, conditions, and deaths resulting from and Cosmetic Act (the FD&C Act) (21 Associate Commissioner for Policy. vaccines described in the Vaccine Injury U.S.C. 355(i)) became effective: [FR Doc. 2015–09522 Filed 4–23–15; 8:45 am] Table (the Table) set forth at Section December 18, 2005. FDA has verified BILLING CODE 4164–01–P 2114 of the PHS Act or as set forth at the applicant’s claim that the date the 42 CFR 100.3, as applicable. This Table investigational new drug application lists for each covered childhood vaccine became effective was on December 18, DEPARTMENT OF HEALTH AND the conditions that may lead to 2005. HUMAN SERVICES compensation and, for each condition, 2. The date the application was the time period for occurrence of the Health Resources and Services tkelley on DSK3SPTVN1PROD with NOTICES initially submitted with respect to the first symptom or manifestation of onset human drug product under section Administration or of significant aggravation after 505(b) of the FD&C Act: March 29, 2012. vaccine administration. Compensation National Vaccine Injury Compensation FDA has verified the applicant’s claim may also be awarded for conditions not Program; List of Petitions Received that the new drug application (NDA) for listed in the Table and for conditions KYNAMRO (NDA 203568) was AGENCY:Health Resources and Services that are manifested outside the time submitted on March 29, 2012. Administration, HHS. periods specified in the Table, but only VerDate Sep<11>2014 17:30 Apr 23, 2015 Jkt 235001 PO 00000 Frm 00070 Fmt 4703 Sfmt 4703 E:\FR\FM\24APN1.SGM 24APN1

Federal Register / Vol. 80, No. 79 / Friday, April 24, 2015 / Notices 23037 if the petitioner shows that the submission. Chapter 35 of title 44, 28. Kristen Silverio on behalf of G. L., condition was caused by one of the United States Code, related to Phoenix, Arizona, Court of Federal listed vaccines. paperwork reduction, does not apply to Claims No: 15–0235V Section 2112(b)(2) of the PHS Act, 42 29. Phyllis Phipps, Bluffton, Indiana, Court information required for purposes of of Federal Claims No: 15–0238V U.S.C. 300aa–12(b)(2), requires that carrying out the Program. 30. Travis Morgan, Franklin, Tennessee, ‘‘[w]ithin 30 days after the Secretary Dated: April 17, 2015. Court of Federal Claims No: 15–0239V receives service of any petition filed 31. Carl S. Fish, Folsom, California, Court of James Macrae, under section 2111 the Secretary shall Federal Claims No: 15–0244V Acting Administrator. publish notice of such petition in the 32. Rami Hatter, Dale City, California, Court Federal Register.’’ Set forth below is a List of Petitions Filed of Federal Claims No: 15–0245V list of petitions received by HRSA on 33. Tarah Gramza on behalf of J. G., Mesa, 1. Leanna Babb, Yuma, Arizona, Court of Arizona, Court of Federal Claims No: 15– March 1, 2015, through March 31, 2015. Federal Claims No: 15–0195V This list provides the name of 0247V 2. Avery Kranz and Alyssa Kranz on behalf 34. Angela Bogue, Louisburg, North Carolina, petitioner, city and state of vaccination of M. K., Millburn, New Jersey, Court of Court of Federal Claims No: 15–0250V (if unknown then city and state of Federal Claims No: 15–0196V 35. Joseph Willett, Wake Forest, North person or attorney filing claim), and 3. Avery Kranz, Millburn, New Jersey, Court Carolina, Court of Federal Claims No: case number. In cases where the Court of Federal Claims No: 15–0197V 15–0252V has redacted the name of a petitioner 4. Carol Williams, Morgantown, West 36. Scott Siciliano and Kathleen Siciliano on and/or the case number, the list reflects Virginia, Court of Federal Claims No: 15– behalf of E. S., Smithtown, New York, 0198V Court of Federal Claims No: 15–0253V such redaction. 5. Thomas Holland, Cataumet, Section 2112(b)(2) also provides that 37. Janet Florence, Glassboro, New Jersey, Massachusetts, Court of Federal Claims Court of Federal Claims No: 15–0255V the special master ‘‘shall afford all No: 15–0199V interested persons an opportunity to 38. Allison Boman on behalf of R. B., Rock 6. Mario Caruso, Clovis, California, Court of Springs, Wyoming, Court of Federal submit relevant, written information’’ Federal Claims No: 15–0200V Claims No: 15–0256V relating to the following: 7. Marilyn Akyuz, Brooklyn, New York, 39. Jordan Holtz, Sussex, Wisconsin, Court of 1. The existence of evidence ‘‘that Court of Federal Claims No: 15–0201V Federal Claims No: 15–0257V there is not a preponderance of the 8. Andrew Bussa, Boston, Massachusetts, 40. Robert Richie, Atoka, Oklahoma, Court of evidence that the illness, disability, Court of Federal Claims No: 15–0202V Federal Claims No: 15–0258V injury, condition, or death described in 9. Peggy Lafon, Crowley, Texas, Court of 41. Sandra E. Horvath, San Jose, California, Federal Claims No: 15–0203V the petition is due to factors unrelated 10. Rosemary St. George, Boston, Court of Federal Claims No: 15–0260V to the administration of the vaccine 42. Lawrence Marra, Jr., Bethlehem, Massachusetts, Court of Federal Claims described in the petition,’’ and Pennsylvania, Court of Federal Claims No: 15–0204V 2. Any allegation in a petition that the No: 15–0261V 11. David G. Smith, Billerica, Massachusetts, petitioner either: 43. Ameena Jaafar on behalf of A. M., Court of Federal Claims No: 15–0205V a. ‘‘Sustained, or had significantly Windsor, Connecticut, Court of Federal 12. Carin Ing-Marie Malkin, Sarasota, Florida, Court of Federal Claims No: 15–0206V Claims No: 15–0267V aggravated, any illness, disability, 44. Brian Badger, Owensboro, Kentucky, injury, or condition not set forth in the 13. Tamie Blesi, Minneapolis, Minnesota, Court of Federal Claims No: 15–0208V Court of Federal Claims No: 15–0273V Vaccine Injury Table but which was 45. John Harbrucker, Kansas City, Kansas, 14. Tamie Blesi, Minneapolis, Minnesota, caused by’’ one of the vaccines referred Court of Federal Claims No: 15–0274V Court of Federal Claims No: 15–0209V to in the Table, or 15. James Collins, Jr., Concord, North 46. Maureen McGrath, Sturgeon Bay, b. ‘‘Sustained, or had significantly Carolina, Court of Federal Claims No: Wisconsin, Court of Federal Claims No: aggravated, any illness, disability, 15–0210V 15–0275V injury, or condition set forth in the 16. Annabella Chin, Pembroke, Florida, Court 47. Jane Privitera, Baldwin, New York, Court Vaccine Injury Table the first symptom of Federal Claims No: 15–0214V of Federal Claims No: 15–0276V 17. Tisia Green, Cheektowaga, New York, 48. Raquel Davis on behalf of M. D., Boston, or manifestation of the onset or Court of Federal Claims No: 15–0218V Massachusetts, Court of Federal Claims significant aggravation of which did not No: 15–0277V occur within the time period set forth in 18. Tate Takahashi, Honolulu, Hawaii, Court of Federal Claims No: 15–0219V 49. Janice Schroeder, Austin, Texas, Court of the Table but which was caused by a 19. Dorothy Keegan, Rochester, New York, Federal Claims No: 15–0278V vaccine’’ referred to in the Table. Court of Federal Claims No: 15–0220V 50. Brittany Stallings Benoit and Arsene In accordance with Section 20. Brandene LaPorte, Philadelphia, Benoit on behalf of Gabriel Cash Benoit, 2112(b)(2), all interested persons may Pennsylvania, Court of Federal Claims Deceased, Quitman, Mississippi, Court of submit written information relevant to No: 15–0221V Federal Claims No: 15–0279V the issues described above in the case of 21. Melvin Keith Castle, New Bern, North 51. Annette Dominguez and Lydia Fazekas the petitions listed below. Any person Carolina, Court of Federal Claims No: on behalf of Rebecca C. Arana, Deceased, 15–0222V Beverly Hills, California, Court of choosing to do so should file an original 22. Sarah Yoon on behalf of N.Y., Valencia, Federal Claims No: 15–0280V and three (3) copies of the information 52. Rita Glynn, St. Paul, Minnesota, Court of California, Court of Federal Claims No: with the Clerk of the U.S. Court of 15–0224V Federal Claims No: 15–0283V Federal Claims at the address listed 23. Bernard Halverson on behalf of Susan 53. Malissa Ajeti, Gilroy, California, Court of above (under the heading FOR FURTHER Halverson, Deceased, Somers Point, New Federal Claims No: 15–0284V INFORMATION CONTACT), with a copy to Jersey, Court of Federal Claims No: 15– 54. Shawn Orgel-Olson, Boston, HRSA addressed to Director, Division of 0227V Massachusetts, Court of Federal Claims Injury Compensation Programs, 24. Jean L. Buck, Las Vegas, Nevada, Court No: 15–0285V of Federal Claims No: 15–0231V 55. George Swaiss, Santa Clara, California, tkelley on DSK3SPTVN1PROD with NOTICES Healthcare Systems Bureau, 5600 25. Joseph Bourche, Boulder, Colorado, Court Court of Federal Claims No: 15–0286V Fishers Lane, Room 11C–26, Rockville, of Federal Claims No: 15–0232V 56. Ann Wyborski, Vienna, Virginia, Court of MD 20857. The Court’s caption 26. Keith Saunders, Onawa, Iowa, Court of Federal Claims No: 15–0295V (Petitioner’s Name v. Secretary of Health Federal Claims No: 15–0233V 57. Nadara Shives, Boston, Massachusetts, and Human Services) and the docket 27. Mary Axelson on behalf of A. A., Court of Federal Claims No: 15–0296V number assigned to the petition should Phoenix, Arizona, Court of Federal 58. Joseph Sullivan, Sarasota, Florida, Court be used as the caption for the written Claims No: 15–0234V of Federal Claims No: 15–0300V VerDate Sep<11>2014 17:30 Apr 23, 2015 Jkt 235001 PO 00000 Frm 00071 Fmt 4703 Sfmt 4703 E:\FR\FM\24APN1.SGM 24APN1

23038 Federal Register / Vol. 80, No. 79 / Friday, April 24, 2015 / Notices 59. Robert VanOsdol, Dallas, Texas, Court of Contact Person: Suzan Nadi, Ph.D., as amended. The contract proposals and Federal Claims No: 15–0303V Scientific Review Officer, Center for the discussions could disclose 60. Melissa Intini on behalf of Vanni Mae Scientific Review, National Institutes of confidential trade secrets or commercial Intini, Fort Bragg, North Carolina, Court Health, 6701 Rockledge Drive, Room 5217B, property such as patentable material, of Federal Claims No: 15–0304V MSC 7846, Bethesda, MD 20892, 301–435– 61. Erich Micheal Gram, Huntersville, North 1259, nadis@csr.nih.gov. and personal information concerning Carolina, Court of Federal Claims No: This notice is being published less than 15 individuals associated with the contract 15–0305V days prior to the meeting due to the timing proposals, the disclosure of which 62. Edward M. Haney, San Pablo, California, limitations imposed by the review and would constitute a clearly unwarranted Court of Federal Claims No: 15–0310V funding cycle. invasion of personal privacy. 63. Charles Rohrer, Cedar Rapids, Iowa, Name of Committee: Center for Scientific Name of Committee: National Center for Court of Federal Claims No: 15–0311V Review Special Emphasis Panel, PAR–12– Advancing Translational Sciences Special 64. Jovan Ragia, Dallas, Texas, Court of 138: NHLBI Systems Biology Collaborations. Emphasis Panel LRP. Federal Claims No: 15–0312V Date: May 18–19, 2015. Date: June 2–3, 2015. 65. Karen Ryf, Oshkosh, Wisconsin, Court of Time: 10:00 a.m. to 6:00 p.m. Time: 8:00 a.m. to 5:00 p.m. Federal Claims No: 15–0313V Agenda: To review and evaluate grant Agenda: To review and evaluate contract 66. Jaymeeni Patel, Atlanta, Georgia, Court of applications. proposals. Federal Claims No: 15–0318V Place: National Institutes of Health, 6701 Place: National Institutes of Health, One 67. Angela Waters, Seneca, South Carolina, Rockledge Drive, Bethesda, MD 20892, Democracy Plaza, 6701 Democracy Court of Federal Claims No: 15–0320V (Virtual Meeting). Boulevard, Bethesda, MD 20892 (Virtual 68. Beatrice Thomure, Boston, Contact Person: Ai-Ping Zou, MD, Ph.D., Meeting). Massachusetts, Court of Federal Claims Scientific Review Officer, Center for Contact Person: Barbara J. Nelson, Ph.D., No: 15–0322V Scientific Review, National Institutes of Scientific Review Officer, Office of Scientific 69. Annmarie Auer, Boston, Massachusetts, Health, 6701 Rockledge Drive, Room 4118, Review, National Center for Advancing Court of Federal Claims No: 15–0323V MSC 7814, Bethesda, MD 20892, 301–408– Translational Sciences (NCATS), National 70. Sara Olivia Cain, Raleigh, North Carolina, 9497, zouai@csr.nih.gov. Institutes of Health, 6701 Democracy Blvd., Court of Federal Claims No: 15–0325V Name of Committee: Center for Scientific Democracy 1, Room 1080, Bethesda, MD 71. Nicholas Reinking and Hilary Katherine Review Special Emphasis Panel, PAR–12– 20892–4874, 301–435–0806, nelsonbj@ Reinking on behalf of M. R., Phoenix, 138: NHLBI Systems Biology Collaborations. mail.nih.gov. Arizona, Court of Federal Claims No: 15– Date: May 18–19, 2015. (Catalogue of Federal Domestic Assistance 0326V Time: 10:00 a.m. to 6:00 p.m. Program Nos. 93.859, Pharmacology, 72. Philip Power and April Power on behalf Agenda: To review and evaluate grant Physiology, and Biological Chemistry of C. P., Cary, North Carolina, Court of applications. Research; 93.350, B—Cooperative Federal Claims No: 15–0327V Place: National Institutes of Health, 6701 Agreements; 93.859, Biomedical Research [FR Doc. 2015–09602 Filed 4–23–15; 8:45 am] Rockledge Drive, Bethesda, MD 20892, and Research Training, National Institutes of BILLING CODE 4165–15–P (Virtual Meeting). Health, HHS) Contact Person: Katherine M Malinda, Dated: April 20, 2015. Ph.D., Scientific Review Officer, Center for DEPARTMENT OF HEALTH AND Scientific Review, National Institutes of David Clary, HUMAN SERVICES Health, 6701 Rockledge Drive, Room 4140, Program Analyst, Office of Federal Advisory MSC 7814, Bethesda, MD 20892, 301–435– Committee Policy. National Institutes of Health 0912, Katherine_Malinda@csr.nih.gov. [FR Doc. 2015–09502 Filed 4–23–15; 8:45 am] (Catalogue of Federal Domestic Assistance BILLING CODE 4140–01–P Center for Scientific Review; Notice of Program Nos. 93.306, Comparative Medicine; Closed Meetings 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, DEPARTMENT OF HEALTH AND Pursuant to section 10(d) of the 93.846–93.878, 93.892, 93.893, National HUMAN SERVICES Federal Advisory Committee Act, as Institutes of Health, HHS) amended (5 U.S.C. App.), notice is Dated: April 20, 2015. National Institutes of Health hereby given of the following meetings. Melanie J. Gray, The meetings will be closed to the National Human Genome Research Program Analyst, Office of Federal Advisory public in accordance with the Committee Policy. Institute; Notice of Closed Meetings provisions set forth in sections [FR Doc. 2015–09500 Filed 4–23–15; 8:45 am] Pursuant to section 10(d) of the 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Federal Advisory Committee Act, as BILLING CODE 4140–01–P as amended. The grant applications and amended (5 U.S.C. App.), notice is the discussions could disclose hereby given of the following meetings. confidential trade secrets or commercial DEPARTMENT OF HEALTH AND The meetings will be closed to the property such as patentable material, HUMAN SERVICES public in accordance with the and personal information concerning provisions set forth in sections individuals associated with the grant National Institutes of Health 552b(c)(4) and 552b(c)(6), title 5 U.S.C., applications, the disclosure of which as amended. The grant applications and would constitute a clearly unwarranted National Center for Advancing the discussions could disclose invasion of personal privacy. Translational Sciences; Notice of confidential trade secrets or commercial Name of Committee: Center for Scientific Closed Meeting property such as patentable material, Review Special Emphasis Panel, Epigenetics, Pursuant to section 10(d) of the and personal information concerning Heparins, and Neurologic Disorders. tkelley on DSK3SPTVN1PROD with NOTICES Federal Advisory Committee Act, as individuals associated with the grant Date: May 1, 2015. applications, the disclosure of which Time: 1:00 p.m. to 2:00 p.m. amended (5 U.S.C. App.), notice is hereby given of the following meeting. would constitute a clearly unwarranted Agenda: To review and evaluate grant applications. The meeting will be closed to the invasion of personal privacy. Place: National Institutes of Health, 6701 public in accordance with the Name of Committee: Center for Inherited Rockledge Drive, Bethesda, MD 20892, provisions set forth in sections Disease Research Access Committee. (Telephone Conference Call). 552b(c)(4) and 552b(c)(6), title 5 U.S.C., Date: May 7, 2015. VerDate Sep<11>2014 17:30 Apr 23, 2015 Jkt 235001 PO 00000 Frm 00072 Fmt 4703 Sfmt 4703 E:\FR\FM\24APN1.SGM 24APN1


Document Created: 2015-12-16 08:42:54
Document Modified: 2015-12-16 08:42:54
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
ActionNotice.
ContactFor information about requirements for filing petitions, and the Program in general, contact the Clerk, United States Court of Federal Claims, 717 Madison Place NW., Washington, DC 20005, (202) 357-6400. For information on HRSA's role in the Program, contact the Director, National Vaccine Injury Compensation Program, 5600 Fishers Lane, Room 11C-26, Rockville, MD 20857; (301) 443-6593.
FR Citation80 FR 23036 
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR